The confirmation of positive topline results and identification of a maximum tolerated dose is a significant milestone for Alzamend Neuro. This news is likely to boost investor confidence, as it suggests progress in their drug development process. Such advancements are typically viewed positively by the market, potentially leading to an increase in stock prices.